Welcome to our dedicated page for Verona Pharma SEC filings (Ticker: VRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verona Pharma鈥檚 SEC documents don鈥檛 just list numbers鈥攖hey reveal how each Phase III readout, cash runway estimate, or licensing discussion can reshape the future of COPD treatment. Yet separating critical trial updates from 200-page technical appendices is time-consuming.
That鈥檚 why Stock Titan pairs every filing with AI-powered summaries that explain Verona Pharma SEC filings explained simply. Need the latest Verona Pharma quarterly earnings report 10-Q filing? Our engine extracts R&D spend, burn rate and milestone guidance in seconds. Curious about board decisions? The platform flags Verona Pharma proxy statement executive compensation details and contextualizes option awards against peer biotechs.
AG真人官方-time feeds surface Verona Pharma Form 4 insider transactions real-time, letting you see Verona Pharma insider trading Form 4 transactions moments after they hit EDGAR. Click once to view an AI summary that highlights buying or selling trends and links to deeper Verona Pharma executive stock transactions Form 4 analytics. When management issues an 8-K on topline efficacy, our system posts the document within minutes, with a note titled 鈥淰erona Pharma 8-K material events explained鈥�.
Whether you鈥檙e preparing for FDA Advisory Committee chatter or modeling dilution risk, our coverage spans every form鈥擲-1s, S-3s, 424Bs, plus the flagship Verona Pharma annual report 10-K simplified. Professionals use these insights to validate assumptions, track fundraising capacity, and benchmark trial timelines. If you鈥檙e still scrolling through PDFs, try understanding Verona Pharma SEC documents with AI and experience Verona Pharma earnings report filing analysis that saves hours and sharpens decisions.
Verona Pharma plc (VRNA) 鈥� Form 4 insider transaction. CFO Mark W. Hahn reported activity dated 1 Aug 2025.
- Acquisition (Code M): 255,696 Ordinary Shares (represented by ADSs) were issued at $0 on conversion of previously earned Restricted Stock Units (RSUs).
- Disposition (Code S): 208,912 Ordinary Shares were sold at an average $13.1437 per share under a pre-arranged Rule 10b5-1 plan executed 24 May 2022; purpose stated as tax-withholding on RSU vesting.
- Post-transaction ownership: 12,464,968 Ordinary Shares held directly and 1,189,792 RSUs remaining (equivalent to 1,189,792 Ordinary Shares) plus 800,000 performance-based RSUs.
- New RSU vesting schedules extend through Aug 2026, tied to the first commercial sale of ensifentrine and achievement of Q1-25 performance metrics.
No cash outlay for the share acquisition; sale represents roughly 1.7 % of total direct Ordinary Share holdings, indicating continued substantial insider ownership.
Form 4 filed by David R. Ebsworth, Director of Verona Pharma plc (VRNA) dated 08/05/2025 reporting transactions on 08/01/2025. The report discloses a grant of RSUs covering 24,000 Ordinary Shares (presented as the Ordinary Share equivalent of ADS-based RSUs) and a mandatory "sell-to-cover" sale of 1,904 Ordinary Shares at $13.1437 per share to satisfy tax withholding upon vesting. The RSUs vest 25% on each of Aug 1, 2025; Nov 1, 2025; Feb 1, 2026; and May 1, 2026 and have no expiration. Following the reported transactions the filing shows direct beneficial ownership of 880,499 Ordinary Shares and indirect ownership of 617,600 Ordinary Shares via Ebsworth GmbH. Form signed by attorney-in-fact on 08/05/2025.
FAQ
What is the current stock price of Verona Pharma (VRNA)?
What is the market cap of Verona Pharma (VRNA)?
